Aptose Biosciences Inc. announced on February 23, 2026, an amended agreement with Hanmi Pharmaceuticals for the acquisition of all its common shares and a new $11.1 million funding agreement, with a loan cap of $4.2 million per advance at 6% interest to support business operations related to Tuspetinib.